Charles River Laboratories International CRL
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Charles River Laboratories International (CRL) Business Model and Operations Summary
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Key Insights
Charles River Laboratories International (CRL) Core Market Data and Business Metrics
Latest Closing Price
$145.99Market Cap
$7.46 BillionPrice-Earnings Ratio
729.95Total Outstanding Shares
51.14 Million SharesTotal Employees
20,100Dividend
No dividendIPO Date
June 23, 2000SIC Description
Services-commercial Physical & Biological ResearchPrimary Exchange
New York Stock ExchangeHeadquarters
251 Ballardvale St, Wilmington, MA, 01887
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
December 31, 2023 to December 28, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-245.09 Million |
| Net Cash Flow, Continuing | $-61.44 Million |
| Net Cash Flow From Financing Activities | $-550.93 Million |
| Net Cash Flow | $-78.91 Million |
| Exchange Gains/Losses | $-17.47 Million |
| Net Cash Flow From Financing Activities, Continuing | $-550.93 Million |
Income Statement
December 31, 2023 to December 28, 2024
| Metric | Value |
|---|---|
| Selling, General, and Administrative Expenses | $751.00 Million |
| Revenues | $4.05 Billion |
| Preferred Stock Dividends And Other Adjustments | $11.91 Million |
| Income Tax Expense/Benefit, Current | $135.02 Million |
| Operating Income/Loss | $227.35 Million |
| Income/Loss From Continuing Operations After Tax | $25.29 Million |
Comprehensive Income
December 31, 2023 to December 28, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-98.48 Million |
| Other Comprehensive Income/Loss | $-123.77 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $237,000 |
| Comprehensive Income/Loss Attributable To Parent | $-98.72 Million |
Balance Sheet
December 31, 2023 to December 28, 2024
| Metric | Value |
|---|---|
| Equity | $3.47 Billion |
| Current Liabilities | $994.10 Million |
| Inventory | $278.54 Million |
| Fixed Assets | $1.60 Billion |
| Accounts Payable | $140.34 Million |
| Noncurrent Assets | $6.13 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||